Rhumbline Advisers raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 419,727 shares of the medical research company's stock after purchasing an additional 12,539 shares during the quarter. Rhumbline Advisers owned 0.23% of IQVIA worth $82,480,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the 3rd quarter valued at $27,000. Synergy Asset Management LLC purchased a new position in IQVIA during the fourth quarter valued at approximately $33,000. Avior Wealth Management LLC raised its position in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. increased its position in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, Concord Wealth Partners bought a new position in shares of IQVIA in the 3rd quarter worth $57,000. Institutional investors and hedge funds own 89.62% of the company's stock.
Wall Street Analysts Forecast Growth
IQV has been the topic of a number of analyst reports. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday. The Goldman Sachs Group reduced their price objective on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $251.22.
Read Our Latest Stock Report on IQV
IQVIA Price Performance
Shares of NYSE IQV traded up $3.39 during trading on Wednesday, hitting $196.54. The company had a trading volume of 1,700,843 shares, compared to its average volume of 1,412,664. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a fifty day simple moving average of $199.95 and a two-hundred day simple moving average of $217.09. The firm has a market capitalization of $34.61 billion, a price-to-earnings ratio of 26.21, a price-to-earnings-growth ratio of 1.98 and a beta of 1.48.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.86 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director John G. Danhakl bought 1,275 shares of the firm's stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is owned by insiders.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
